Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEOGENOMICS, INC.

(NEO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NeoGenomics : Needham Adjusts NeoGenomics' Price Target to $55 From $65; Buy Rating Kept

05/06/2021 | 06:49am EDT


ę MT Newswires 2021
All news about NEOGENOMICS, INC.
10/19NEOGENOMICS : Subsidiary Enters Into Clinical Trial Collaboration With Princess Margaret C..
MT
10/19NEOGENOMICS' : Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Prin..
PU
10/14Health Care Stocks Moderate Slightly in Afternoon Trading
MT
10/14NEOGENOMICS : Shares Rise After Raymond James Upgrade
MT
10/14Health Care Stocks Keeping Pace With Rising Thursday Markets
MT
10/14NEOGENOMICS : Raymond James Upgrades NeoGenomics to Outperform from Market Perform, Sets $..
MT
10/13NEOGENOMICS : Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
PU
10/12NEOGENOMICS : Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Dou..
PU
10/12NEOGENOMICS INC : Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
10/12NeoGenomics, Inc. Announces Board Changes
CI
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
Financials (USD)
Sales 2021 498 M - -
Net income 2021 16,3 M - -
Net Debt 2021 245 M - -
P/E ratio 2021 392x
Yield 2021 -
Capitalization 5 641 M 5 641 M -
EV / Sales 2021 11,8x
EV / Sales 2022 10,2x
Nbr of Employees 1 700
Free-Float 96,0%
Chart NEOGENOMICS, INC.
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 45,87 $
Average target price 56,45 $
Spread / Average Target 23,1%
EPS Revisions
Managers and Directors
Mark Mallon Chief Executive Officer & Director
George A. Cardoza President & Chief Operating Officer-Lab Operations
Kathryn B. McKenzie Chief Financial Officer
Lynn A. Tetrault Non-Executive Chairman
Steven A. Ross Chief Information Officer & Vice President
Sector and Competitors